Is ndra stock strong buy today and is it good invest further

**Endra Life Sciences (NDRA) is not a strong buy today, and it is not a good investment to consider further.** Here's why: 1. **Technical Indicators Suggest Caution**: The stock's RSI is at 53.01, which is neither overbought nor oversold. However, the KDJ indicator is at 10.87, which suggests that the stock may be approaching an oversold condition. The MACD is at -0.12, indicating a potential bearish momentum. |code|Ticker|Name|Date|RSI|KDJ|MACD|market_code| |---|---|---|---|---|---|---|---| |NDRA|NDRA.O|Endra Life Sciences|20250723|53.0061|10.8652|-0.1178|186| 2. **Moving Averages Indicate a Bearish Trend**: The stock's 5-day moving average is $6.88, its 10-day moving average is $7.39, and its 50-day moving average is $4.37. The fact that the shorter-term moving averages are higher than the longer-term moving averages suggests that the stock has been in a downtrend, and this could continue. |code|Ticker|Name|Date|Moving Average|market_code| |---|---|---|---|---|---| |NDRA|NDRA.O|Endra Life Sciences|20250723|6.8840|186| 3. **Support and Resistance Levels Are Neutral**: The support level is at $6.3, and the resistance level is at $9.5. The stock is currently trading close to the support level, which could be a point of concern if the stock were to break below this level. |code|Ticker|Name|Date|Support Level|Resistance Level|market_code| |---|---|---|---|---|---|---| |NDRA|NDRA.O|Endra Life Sciences|20250723|6.3010|9.5000|186| 4. **Financial Ratios Suggest Weakness**: The company has a negative P/E ratio of -0.53, which indicates that the company is not profitable as currently reported. The Price to Book Ratio is 2.97, which suggests that the stock may be overvalued relative to its book value. |code|Ticker|Name|Date|P/E(TTM)|P/S|Price to Book Ratio|market_code| |---|---|---|---|---|---|---|---| |NDRA|NDRA.O|Endra Life Sciences|20240724|-0.563805||1.4631675057298579|186| |NDRA|NDRA.O|Endra Life Sciences|20240725|-0.585772||1.520174031927125|186| |NDRA|NDRA.O|Endra Life Sciences|20240726|-0.585772||1.520174031927125|186| |NDRA|NDRA.O|Endra Life Sciences|20240729|-0.578449||1.501171856528036|186| |NDRA|NDRA.O|Endra Life Sciences|20240730|-0.629704||1.6341870843216593|186| |NDRA|NDRA.O|Endra Life Sciences|20240731|-0.578449||1.501171856528036|186| |NDRA|NDRA.O|Endra Life Sciences|20240801|-0.585772||1.520174031927125|186| |NDRA|NDRA.O|Endra Life Sciences|20240802|-0.571127||1.4821696811289469|186| |NDRA|NDRA.O|Endra Life Sciences|20240805|-0.490584||1.2731457517389673|186| |NDRA|NDRA.O|Endra Life Sciences|20240806|-0.490584||1.2731457517389673|186| 5. **Recent News Indicates Financial and Operational Challenges**: The company has been facing significant financial and operational challenges, with no revenue generation and persistent losses. The lack of profitability and unattractive valuation metrics weigh heavily on the stock’s potential. 6. **Immediate Improvements in Financial Performance and Strategic Direction are Crucial**: The company intends to broaden its patented TAEUS technology beyond liver health to include applications like temperature monitoring for ablation therapies and vascular and tissue perfusion. These developments could potentially drive future growth, but they are not yet reflected in the current stock price. In conclusion, despite some short-term technical momentum, the lack of profitability and unattractive valuation metrics weigh heavily on the stock’s potential. Immediate improvements in financial performance and strategic direction are crucial for enhancing its outlook. Therefore, it is not a strong buy today, and it is not a good investment to consider further.